PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.16 USD | +4.02% |
|
-12.51% | -31.69% |
| Apr. 15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| Apr. 12 | Pharvaris Files Mixed Shelf | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
17.27
EUR
Average target price
31.03
EUR
Spread / Average Target
+79.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.69% | 991M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Oppenheimer Adjusts Pharvaris Price Target to $24 From $22, Maintains Outperform Rating
